首页 | 本学科首页   官方微博 | 高级检索  
     


Drug‐coated balloon: Long‐term outcome from a real world three‐center experience
Authors:Carlo Zivelonghi MD  Matteo Ghione MD  Giovanni Benfari MD  Magdalena Cuman MD  Alfredo Fede MD  Mattia Lunardi MD  Stefano Cordone MD  Marco Botta MD  Andrea Pacchioni MD  Pietro Bellone MD  Bernhard Reimers MD  Flavio L. Ribichini MD
Affiliation:1. Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy;2. Department of Cardiology, Ospedale San Paolo, Savona, Italy;3. Department of Cardiology, Mirano Hospital, Mirano, Italy
Abstract:

Objectives

In‐stent restenosis (ISR) and diffuse small vessel disease still represent challenging subsets for percutaneous coronary interventions, also in the new‐generation DES era. We aim at reporting on the long‐term clinical outcome of drug‐coated balloons (DCB) in all‐comers population.

Methods

Consecutive patients treated with DCB between January 2011 and December 2014 were retrospectively studied in three centers of northern Italy. The measured end‐points were cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), and major adverse cardiac events (MACE) defined as combination of cardiac death, MI, and TLR.

Results

We included 143 patients. Of the 167 lesions treated, 41 (24.5%) were de novo lesions in small coronary vessels (<2.5 mm) and 126 (75.4%) were ISR. Among ISR lesions, 78.5% were DES‐ISR, 32.5% were focal, 15.8% multifocal, 30.1% diffuse, 18.2% proliferative, and 3.1% were total occlusions. Procedural success was achieved in 94.6% of cases. Overall survival free from MACEs was 91.6% at 12 months, and 75.3% at 48 months, with a total of 3 cardiac deaths, 8 MI, and 27 TLR. No thrombotic event occurred in the treated segments. There were no differences in MACESs between the ISR and de novo lesions groups. At multivariate analysis, acute coronary syndromes, previous MI, previous surgical revascularization, peripheral arterial disease and diabetes were independent predictors of MACEs at long‐term follow‐up.

Conclusions

DCB proved a valid revascularization strategy in an all‐comers population of patients with ISR and de novo lesions in small vessels, with an acceptable rate of cardiac events up to 48 months follow‐up.
Keywords:drug‐coated balloon  in‐stent restenosis  small vessel disease
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号